Spots Global Cancer Trial Database for stage iv
Every month we try and update this database with for stage iv cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Phase II Trial of Pembrolizumab With Trastuzumab and Chemotherapy in Advanced HER2 Positive Esophagogastric (EG) Cancer | NCT02954536 | Esophageal Canc... Gastric Cancer | pembrolizumab trastuzumab capecitabine cisplatin Oxaliplatin 5-Fluorouracil | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| Study to Evaluate Efficacy of CO-1.01 as Second Line Therapy for Gemcitabine-Refractory Stage IV Pancreatic Adenocarcinoma | NCT01233375 | Metastatic Panc... | CO-1.01 | 18 Years - | Clovis Oncology, Inc. | |
| Cabozantinib for Metastatic Triple Negative BrCa | NCT01738438 | Breast Cancer | Cabozantinib | 18 Years - | Dana-Farber Cancer Institute | |
| Nivolumab and Tumor Infiltrating Lymphocytes (TIL) in Advanced Non-Small Cell Lung Cancer | NCT03215810 | Non-Small Cell ... Metastatic Non-... Squamous Cell C... Advanced NSCLC Adenosquamous C... Adenocarcinomas | Tumor-infiltrat... Nivolumab Cyclophosphamid... Fludarabine Tumor-infiltrat... Interleukin-2 (... | 18 Years - | H. Lee Moffitt Cancer Center and Research Institute | |
| Dacomitinib + Pemetrexed for Patients With Advanced Non-squamous Non-small Cell Lung Cancer (NSCLC) | NCT01918761 | Non Small Cell ... | Dacomitinib, Pe... | 18 Years - | Central European Cooperative Oncology Group | |
| The Benefit of Surgery in Stage IV of Breast Cancer | NCT04697043 | Breast Cancer S... | Systemic therap... | 18 Years - 90 Years | Tehran University of Medical Sciences | |
| Phase II Trial of Ontak With Metastatic Melanoma | NCT00299689 | Malignant Melan... | Denileukin dift... | 18 Years - | James Graham Brown Cancer Center | |
| A Study of BIIB022 in Combination With Paclitaxel and Carboplatin in Subjects With Non-Small Cell Lung Cancer | NCT00970580 | Non-Small Cell ... | BIIB022 With Pa... | 18 Years - | Biogen | |
| Aggressive Thoracic Radiotherapy for Stage Ⅳ Non Small Cell Lung Cancer | NCT03565120 | Carcinoma, Non-... Stage IV Thoracic Radiot... | Aggressive Thor... | 18 Years - 80 Years | Jiangmen Central Hospital | |
| Fecal Microbiota Transplant (FMT) in Melanoma Patients | NCT03341143 | Melanoma | Fecal Microbiot... | 18 Years - | University of Pittsburgh | |
| Phase II Study of Erlotinib, an EGFR Inhibitor in Metastatic EGFR-positive 'Triple Receptor-negative' Breast Cancer | NCT00739063 | Breast Cancer | Tarceva | - | M.D. Anderson Cancer Center | |
| The Benefit of Surgery in Stage IV of Breast Cancer | NCT04697043 | Breast Cancer S... | Systemic therap... | 18 Years - 90 Years | Tehran University of Medical Sciences | |
| Stenting and Resection for Stage IV Colorectal Cancer Endoscopic Stenting and Colorectal Resection in Stage IV | NCT03451643 | Colorectal Neop... | ENDOSCOPIC PLAC... | 50 Years - 85 Years | University of Roma La Sapienza | |
| CASPALLO: Allodepleted T Cells Transduced With Inducible Caspase 9 Suicide Gene | NCT00710892 | Acute Lymphobla... Non-Hodgkin's L... Myelodysplastic... Chronic Myeloid... | Allodepleted T ... | - 65 Years | Baylor College of Medicine | |
| A Trial of Atezolizumab and Vigil in Patients With Advanced Gynecological Cancers | NCT03073525 | Advanced Gyneco... Ovarian Cancer Cervical Cancer Uterine Cancer | Vigil Atezolizumab | 18 Years - | Gradalis, Inc. | |
| A Trial of Pembrolizumab and Metformin Versus Pembrolizumab Alone in Advanced Melanoma | NCT03311308 | Advanced Melano... | Pembrolizumab I... Metformin | 18 Years - | University of Pittsburgh | |
| Efficacy and Safety of Olaparib in Pretreated Patients With Measurable Colorectal Cancer, Stratified by Microsatellite Instability (MSI) Status | NCT00912743 | Colorectal Canc... | olaparib | 18 Years - 130 Years | AstraZeneca | |
| Tumor-Infiltrating Lymphocytes And Low-Dose Interleukin-2 Therapy Following Cyclophosphamide And Fludarabine In Patients With Melanoma | NCT01883323 | Metastatic, Sta... | Cyclophosphamid... Fludarabine Tumor-Infiltrat... Low-Dose Interl... | 18 Years - | University Health Network, Toronto | |
| Using Bio Markers to Predict Disease Recurrence and Cognitive Function in High Risk Breast Ca | NCT00756132 | Locally Advance... Breast Cancer | 18 Years - 65 Years | University Health Network, Toronto | ||
| STA-9090(Ganetespib) in Patients With Unresectable Stage III or Stage IV Melanoma | NCT01551693 | Melanoma | STA-9090 | 18 Years - | Dana-Farber Cancer Institute | |
| A Phase I Study of TPI 287 - Temozolomide Combination in Melanoma | NCT01067066 | Melanoma | TPI 287 Temodar (Temozo... | 15 Years - | M.D. Anderson Cancer Center | |
| Sorafenib and Temsirolimus in Treating Patients With Metastatic, Recurrent, or Unresectable Melanoma | NCT01851408 | Melanoma Recurrent Melan... Stage III Melan... Stage IV Melano... | sorafenib tosyl... temsirolimus | 18 Years - | National Cancer Institute (NCI) | |
| Stage IV Surgery Versus Best Medical Therapy | NCT01013623 | Stage IV Resect... | Surgery Surgery plus 2 ... best medical th... | 18 Years - | Saint John's Cancer Institute | |
| A Study of PEGylated Recombinant Human Hyaluronidase in Combination With Nab-Paclitaxel Plus Gemcitabine Compared With Placebo Plus Nab-Paclitaxel and Gemcitabine in Participants With Hyaluronan-High Stage IV Previously Untreated Pancreatic Ductal Adenocarcinoma | NCT02715804 | Pancreatic Duct... | Biological: PEG... Placebo nab-Paclitaxel Gemcitabine | 18 Years - | Halozyme Therapeutics | |
| A Single Arm Study of Ipilimumab Monotherapy in Patients With Previously Treated Unresectable Stage III or IV Melanoma | NCT00289627 | Melanoma | ipilimumab (MDX... | 18 Years - | Bristol-Myers Squibb | |
| Randomized Trial of Concomitant Chemotherapy in Patients With Locally Advanced HNSCC Treated by Radiotherapy-erbitux | NCT00609284 | HNSCC | cetuximab Carboplatin, 5F... Radiotherapy | 18 Years - 70 Years | Groupe Oncologie Radiotherapie Tete et Cou | |
| Fecal Microbiota Transplant (FMT) in Melanoma Patients | NCT03341143 | Melanoma | Fecal Microbiot... | 18 Years - | University of Pittsburgh | |
| Study In Women And Men With Metastatic Breast Cancer That Have Overexpression Of ErbB2 | NCT00281658 | Neoplasms, Brea... | Lapatinib (GW57... Paclitaxel infu... Placebo | 18 Years - | Novartis | |
| Weekly Docetaxel Plus Cisplatin or Oxaliplatin for AGC | NCT00510107 | Stomach Neoplas... Stage IV Recurrent | oxaliplatin Cisplatin | 18 Years - 75 Years | Gachon University Gil Medical Center | |
| Vemurafenib (R05185426) in Poor Performance Status Patients With Unresectable Locally Advanced or Metastatic Melanoma Harboring a V600E/K Mutation | NCT01474551 | Melanoma | vemurafenib | 19 Years - | Memorial Sloan Kettering Cancer Center | |
| Patient-reported Outcome Questionnaire for Women With Metastatic Breast Cancer | NCT01282931 | Metastatic Brea... | 18 Years - | Health Outcomes Solutions | ||
| Matched Unrelated Donor Transplant for Metastatic Renal Cell Carcinoma | NCT00318110 | Metastatic Rena... | NST using MUD f... | 18 Years - 65 Years | Center for International Blood and Marrow Transplant Research | |
| Pilot Study of IV and IP Chemotherapy Plus Abdominal Hyperthermia for Ovarian Ca | NCT00787488 | Ovarian Cancer | Hyperthermia | 18 Years - 72 Years | Duke University | |
| HD IL-2 + Vemurafenib in Patients With BRAF Mutation Positive Metastatic Melanoma | NCT01683188 | Metastatic Mela... | vemurafenib + H... | 18 Years - | Clinigen, Inc. | |
| Dose EScalation Induction of EvERolimus | NCT02387099 | Breast Cancer Hormone Recepto... | 3 weeks Dose In... 3 weeks Convent... Open Label Phas... Standard Care a... | 18 Years - | German Breast Group | |
| Improving Goals of Care Discussion in Advanced Cancer Patients | NCT02374255 | Primary Stage I... Esophageal Colorectal Canc... Glioblastoma Cancer of Stoma... Cancer of Pancr... Melanoma Head or Neck Ca... Stage III Stage IV Lung Cancers Pancreatic Canc... | GoC interventio... | 21 Years - | Icahn School of Medicine at Mount Sinai | |
| S0329, Gemcitabine and Paclitaxel in Treating Patients With Persistent, Recurrent, or Metastatic Head and Neck Cancer | NCT00100789 | Head and Neck C... | gemcitabine paclitaxel | 18 Years - | SWOG Cancer Research Network | |
| MK-0646 Insulin Growth Factor 1 Receptor Antibody in Stage IIIb or IV Metastatic Non-Squamous Lung Cancer | NCT00799240 | Non Small Cell ... | Arm A: Pemetrex... Arm B Pemetrexe... | 18 Years - | University of Kansas Medical Center | |
| Managed Access Program to Provide Access to Alpelisib for Patients With Advanced Breast Cancer | NCT04473040 | HR+, HER2-, Adv... | alpelisib | 18 Years - 99 Years | Novartis | |
| Stage IV Surgery Versus Best Medical Therapy | NCT01013623 | Stage IV Resect... | Surgery Surgery plus 2 ... best medical th... | 18 Years - | Saint John's Cancer Institute | |
| MK-0646 Insulin Growth Factor 1 Receptor Antibody in Stage IIIb or IV Metastatic Non-Squamous Lung Cancer | NCT00799240 | Non Small Cell ... | Arm A: Pemetrex... Arm B Pemetrexe... | 18 Years - | University of Kansas Medical Center | |
| Study Comparing Bevacizumab + Erlotinib vs Erlotinib Alone as First Line Treatment of Patients With EGFR Mutated Advanced Non Squamous Non Small Cell Lung Cancer | NCT02633189 | Non-squamous No... | Erlotinib Bevacizumab | 18 Years - 70 Years | National Cancer Institute, Naples | |
| CAPPA-2: Cisplatin Added to Gemcitabine in Poor Performance Advanced NSCLC Patients | NCT00526643 | Non-Small Cell ... | gemcitabine cisplatin | 18 Years - 70 Years | National Cancer Institute, Naples | |
| Study of Efficacy and Safety of Dabrafenib and Trametinib Combination Therapy in Japanese Patients With BRAF V600E Stage IV NSCLC | NCT02672358 | Non-Small-Cell ... | Dabrafenib Trametinib | 18 Years - | Novartis | |
| A Phase II Study of AZD4877 (a Novel Anti-mitotic Agent) in Advanced Bladder Cancer | NCT00661609 | Bladder Cancer Transitional Ce... Urethra Cancer Ureter Cancer Renal Pelvis Ca... | AZD4877 | 18 Years - | AstraZeneca | |
| A Trial of Atezolizumab and Vigil in Patients With Advanced Gynecological Cancers | NCT03073525 | Advanced Gyneco... Ovarian Cancer Cervical Cancer Uterine Cancer | Vigil Atezolizumab | 18 Years - | Gradalis, Inc. | |
| A Study of PEGylated Recombinant Human Hyaluronidase in Combination With Nab-Paclitaxel Plus Gemcitabine Compared With Placebo Plus Nab-Paclitaxel and Gemcitabine in Participants With Hyaluronan-High Stage IV Previously Untreated Pancreatic Ductal Adenocarcinoma | NCT02715804 | Pancreatic Duct... | Biological: PEG... Placebo nab-Paclitaxel Gemcitabine | 18 Years - | Halozyme Therapeutics | |
| Phase II Study to Assess the Safety and Immunogenicity of recMAGE-A3+AS15 ASCI With or Without Poly IC:LC | NCT01437605 | Melanoma | MAGE-A3 ASCI in... MAGE-A3 ASCI in... | 18 Years - | H. Lee Moffitt Cancer Center and Research Institute | |
| Radiation Therapy and Combination Chemotherapy in Treating Patients With Stage III or Stage IV Head and Neck Cancer | NCT00002774 | Squamous Neck C... | Tirapazamine Cisplatin 5-fluorouracil Radiotherapy (R... | 17 Years - | Stanford University | |
| BrUOG 302:BYL719, Capecitabine and Radiation for Rectal Cancer: A Brown University Oncology Research Group Study | NCT02550743 | Rectal Cancer | BYL719 Capecitabine Radiation | 18 Years - | Brown University | |
| Clinical Study of Fianlimab in Combination With Cemiplimab in Adolescent and Adult Patients With Previously Untreated Unresectable Locally Advanced or Metastatic Melanoma | NCT05352672 | Melanoma | Fianlimab Cemiplimab Pembrolizumab Placebo | 12 Years - | Regeneron Pharmaceuticals | |
| Paclitaxel-Carboplatin-Bevacizumab +/- Nitroglycerin in Metastatic Non-Squamous-Non-Small Cell Lung Cancer | NCT01171170 | Non Small Cell ... | carboplatin pac... Standard treatm... | 18 Years - | Dutch Society of Physicians for Pulmonology and Tuberculosis | |
| Study of REGN 2810 Compared to Platinum-Based Chemotherapies in Participants With Metastatic Non-Small Cell Lung Cancer (NSCLC) | NCT03088540 | Carcinoma，Non-S... Lung Carcinomas... Non-small-cell ... Nonsmall Cell L... | Pemetrexed Paclitaxel Gemcitabine Cisplatin Carboplatin cemiplimab | 18 Years - | Regeneron Pharmaceuticals | |
| M7824 in Combination With Chemotherapy in Stage IV Non-small Cell Lung Cancer (NSCLC) | NCT03840915 | Carcinoma, Non-... | Cisplatin Carboplatin Pemetrexed Nab-paclitaxel Gemcitabine Docetaxel M7824 Carboplatin Carboplatin Bintrafusp alfa Paclitaxel | 18 Years - | EMD Serono | |
| LCCC 1128: Open Label Phase II Trial of the BRAF Inhibitor (Dabrafenib) and the MEK Inhibitor (Trametinib) in Unresectable Stage III and Stage IV BRAF Mutant Melanoma; Correlation of Resistance With the Kinome and Functional Mutations | NCT01726738 | Stage III Melan... Stage IV Melano... Unresectable Me... BRAF Mutant Mel... | BRAF inhibitor ... | 18 Years - | UNC Lineberger Comprehensive Cancer Center | |
| Paclitaxel-Carboplatin-Bevacizumab +/- Nitroglycerin in Metastatic Non-Squamous-Non-Small Cell Lung Cancer | NCT01171170 | Non Small Cell ... | carboplatin pac... Standard treatm... | 18 Years - | Dutch Society of Physicians for Pulmonology and Tuberculosis | |
| Phase II Study of Buparlisib + Docetaxel in Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) Patients | NCT01911325 | Squamous Non-sm... | Buparlisib Buparlisib matc... Docetaxel | 18 Years - | Novartis | |
| Combination Immunotherapy of GM.CD40L Vaccine With CCL21 in Lung Cancer | NCT01433172 | Lung Cancer Adenocarcinoma | Phase I - GM.CD... Phase II - GM.C... Phase II - GM.C... | 18 Years - | H. Lee Moffitt Cancer Center and Research Institute | |
| Study In Women And Men With Metastatic Breast Cancer That Have Overexpression Of ErbB2 | NCT00281658 | Neoplasms, Brea... | Lapatinib (GW57... Paclitaxel infu... Placebo | 18 Years - | Novartis | |
| CAPPA-2: Cisplatin Added to Gemcitabine in Poor Performance Advanced NSCLC Patients | NCT00526643 | Non-Small Cell ... | gemcitabine cisplatin | 18 Years - 70 Years | National Cancer Institute, Naples | |
| Vaccine Therapy in Treating Patients With Stage III-IV or Recurrent Ovarian Cancer | NCT01322802 | Stage III Ovari... Stage III Ovari... Stage IV Ovaria... Stage IV Ovaria... | pUMVC3-hIGFBP-2... laboratory biom... | 18 Years - | University of Washington | |
| Pilot Study of GVAX in Colorectal Cancer Cells | NCT01952730 | Colorectal Canc... | GVAX | 18 Years - | Massachusetts General Hospital | |
| A Study of PEGylated Recombinant Human Hyaluronidase in Combination With Nab-Paclitaxel Plus Gemcitabine Compared With Placebo Plus Nab-Paclitaxel and Gemcitabine in Participants With Hyaluronan-High Stage IV Previously Untreated Pancreatic Ductal Adenocarcinoma | NCT02715804 | Pancreatic Duct... | Biological: PEG... Placebo nab-Paclitaxel Gemcitabine | 18 Years - | Halozyme Therapeutics | |
| Triplet Combination First Line Treatment in Non Small Cell Lung Cancer (NSCLC) | NCT00942825 | Metastatic Non-... | CBP501 + Cispla... Cisplatin + Pem... | 18 Years - | CanBas Co. Ltd. | |
| Non-interventional Observational Study of Helical Tomotherapy for Oligometastatic Colorectal Cancer | NCT00807313 | Colon Cancer Rectal Cancer Colorectal Canc... | 18 Years - | Universitair Ziekenhuis Brussel | ||
| Nivolumab, BMS-936558 in Combination With Relatlimab, BMS-986016 in Patients With Metastatic Melanoma Naïve to Prior Immunotherapy in the Metastatic Setting | NCT03743766 | Melanoma | Relatlimab Nivolumab Relatlimab + Ni... | 18 Years - | University of Pittsburgh | |
| Immunotherapy, Chemotherapy, Radiotherapy and Surgery for Synchronous Oligo-metastatic NSCLC | NCT03965468 | Non-small Cell ... Stage IV Oligometastasis | Durvalumab Carboplatin Paclitaxel Stereotactic bo... Surgical resect... Radical radioth... Tremelimumab | 18 Years - | ETOP IBCSG Partners Foundation | |
| CASPALLO: Allodepleted T Cells Transduced With Inducible Caspase 9 Suicide Gene | NCT00710892 | Acute Lymphobla... Non-Hodgkin's L... Myelodysplastic... Chronic Myeloid... | Allodepleted T ... | - 65 Years | Baylor College of Medicine | |
| European Multicenter Study on Surgical Management of Advanced Thyroid Cancer | NCT05796960 | Thyroid Carcino... Thyroid Cancer Thyroid Neoplas... Thyroid Cancer,... Thyroid Cancer,... Thyroid Medulla... Anaplastic Thyr... | Thyroidectomy w... | 18 Years - | Fondazione Policlinico Universitario Agostino Gemelli IRCCS | |
| Study of REGN 2810 Compared to Platinum-Based Chemotherapies in Participants With Metastatic Non-Small Cell Lung Cancer (NSCLC) | NCT03088540 | Carcinoma，Non-S... Lung Carcinomas... Non-small-cell ... Nonsmall Cell L... | Pemetrexed Paclitaxel Gemcitabine Cisplatin Carboplatin cemiplimab | 18 Years - | Regeneron Pharmaceuticals | |
| Study of Gemcitabine + PEGPH20 vs Gemcitabine Alone in Stage IV Previously Untreated Pancreatic Cancer | NCT01453153 | Stage IV Pancre... | Gemcitabine PEGPH20 Placebo | 18 Years - | Halozyme Therapeutics | |
| STA-9090(Ganetespib) in Patients With Unresectable Stage III or Stage IV Melanoma | NCT01551693 | Melanoma | STA-9090 | 18 Years - | Dana-Farber Cancer Institute | |
| Phase II Study to Assess the Safety and Immunogenicity of recMAGE-A3+AS15 ASCI With or Without Poly IC:LC | NCT01437605 | Melanoma | MAGE-A3 ASCI in... MAGE-A3 ASCI in... | 18 Years - | H. Lee Moffitt Cancer Center and Research Institute | |
| Cabozantinib for Metastatic Triple Negative BrCa | NCT01738438 | Breast Cancer | Cabozantinib | 18 Years - | Dana-Farber Cancer Institute | |
| Study of Glembatumumab Vedotin in gpNMB-Expressing, Advanced or Metastatic SCC of the Lung | NCT02713828 | Squamous Cell C... | Phase I: Glemba... Phase II: Glemb... | 18 Years - | PrECOG, LLC. | |
| Non-interventional Observational Study of Helical Tomotherapy for Oligometastatic Colorectal Cancer | NCT00807313 | Colon Cancer Rectal Cancer Colorectal Canc... | 18 Years - | Universitair Ziekenhuis Brussel | ||
| A Study of BIIB022 in Combination With Paclitaxel and Carboplatin in Subjects With Non-Small Cell Lung Cancer | NCT00970580 | Non-Small Cell ... | BIIB022 With Pa... | 18 Years - | Biogen | |
| Efficacy and Safety Study of Imprime PGG With Cetuximab in Subjects With Stage IV KRAS-Mutated Colorectal Cancer | NCT00912327 | Colorectal Canc... | Imprime PGG | 18 Years - | HiberCell, Inc. | |
| A Trial to See if the Combination of Fianlimab With Cemiplimab Works Better Than Pembrolizumab for Preventing or Delaying Melanoma From Coming Back After it Has Been Removed With Surgery | NCT05608291 | Melanoma | Fianlimab Cemiplimab Pembrolizumab Placebo | 12 Years - | Regeneron Pharmaceuticals | |
| Vemurafenib (R05185426) in Poor Performance Status Patients With Unresectable Locally Advanced or Metastatic Melanoma Harboring a V600E/K Mutation | NCT01474551 | Melanoma | vemurafenib | 19 Years - | Memorial Sloan Kettering Cancer Center |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
